Merck registers Phase 2 MK-1045 trial in B-cell cancers; letermovir CMV study also listed
Two new trial records posted for Merck this week, one Merck-sponsored Phase 2 study and one university-led Phase 4 trial with Merck as collaborator.
Two clinical trial registrations tied to Merck were posted this week, both listed as "not yet recruiting."
- MK-1045, a biological therapy also known as CN201, entered a Phase 2, open-label study (NCT07709000) sponsored by Merck Sharp & Dohme LLC. The trial will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).1 The study plans to enroll 60 participants (estimated)1 and uses a step-up dosing design; participants will receive a priming dose of 1 mg on Day 1, priming dose of 5 mg on Day 4, an intermediate dose of 20 mg on Day 8, and then a weekly target dose of 40-90 mg thereafter for up to approximately 2 years.1
- A separate Phase 4 study of letermovir (NCT07706166) is sponsored by the University of Wisconsin, Madison, with Merck Sharp & Dohme LLC listed as a collaborator. The trial aims to find out whether letermovir can help prevent cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed to CMV.2 Enrollment is estimated at 146 participants2, and participants will take letermovir for 84 days.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.